U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07558668) titled 'A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis' on April 22.
Brief Summary: The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD). The objectives of this study are to determine the safety, tolerability and levels of SYX-5219 in the blood and urine when SYX-5219 is given in each part of the study (SAD, MAD, Food Effect and Participants with AD).
The study will be split into up to 3 parts as follows:
* Part 1 - Single Ascending Dose (SAD) and Food Effect in...